Literature DB >> 18201185

Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection.

Else Marie Agger1, Joseph P Cassidy, Joseph Brady, Karen S Korsholm, Carina Vingsbo-Lundberg, Peter Andersen.   

Abstract

It is known that protection against tuberculosis is mediated primarily by T helper type 1 (Th1) cells but the influence of the Th1/Th2 balance of a vaccination response on the subsequent protection and pathology during infection has not been studied in detail. We designed a panel of Ag85B-ESAT-6 subunit vaccines based on adjuvants with different Th1/Th2-promoting activities and studied cellular responses, bacterial replication and pathology in the lungs of mice infected with Mycobacterium tuberculosis. All vaccines induced cell-mediated and humoral responses but with markedly different interferon-gamma : interleukin-5 (IFN-gamma : IL-5) and immunoglobulin G1 (IgG1) : IgG2 ratios. The vaccines promoted different levels of control of bacterial replication with the most efficient protection being exerted by cationic liposomes containing monophosphoryl lipid A and low to completely absent immunity with conventional aluminium. The level of protection correlated with the amount of IFN-gamma produced in response to the vaccine whereas there was no inverse correlation with the level of IL-5. Characterizing a protective response was an accelerated recruitment of IL-17 and IFN-gamma-producing lymphocytes resulting in the early formation of granulomas containing clustered inducible nitric oxide synthase-activated macrophages. In comparison, non-protected mice exhibited a different inflammatory infiltrate rich in neutrophil granulocytes. This study indicates that the adjuvant component of a tuberculosis vaccine may be crucial in determining the kinetics by which effective granulomas, pivotal in controlling bacterial growth, are formed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201185      PMCID: PMC2566622          DOI: 10.1111/j.1365-2567.2007.02751.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  45 in total

1.  Progress and hindrances in tuberculosis vaccine development.

Authors:  T Mark Doherty; Graham Rook
Journal:  Lancet       Date:  2006-03-18       Impact factor: 79.321

2.  P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues.

Authors:  F Austrup; D Vestweber; E Borges; M Löhning; R Bräuer; U Herz; H Renz; R Hallmann; A Scheffold; A Radbruch; A Hamann
Journal:  Nature       Date:  1997-01-02       Impact factor: 49.962

3.  Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection.

Authors:  E Jouanguy; F Altare; S Lamhamedi; P Revy; J F Emile; M Newport; M Levin; S Blanche; E Seboun; A Fischer; J L Casanova
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

4.  Identification of nitric oxide synthase as a protective locus against tuberculosis.

Authors:  J D MacMicking; R J North; R LaCourse; J S Mudgett; S K Shah; C F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

Review 5.  Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases.

Authors:  R S Liblau; S M Singer; H O McDevitt
Journal:  Immunol Today       Date:  1995-01

6.  Rules of chemokine receptor association with T cell polarization in vivo.

Authors:  C H Kim; L Rott; E J Kunkel; M C Genovese; D P Andrew; L Wu; E C Butcher
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

7.  IL-4 is required for defense against mycobacterial infection.

Authors:  I Sugawara; H Yamada; S Mizuno; Y Iwakura
Journal:  Microbiol Immunol       Date:  2000       Impact factor: 1.955

8.  Disseminated Mycobacterium avium infection in a 20-year-old female with partial recessive IFNgammaR1 deficiency.

Authors:  Paweł Remiszewski; Barbara Roszkowska-Sliz; Jolanta Winek; Ariane Chapgier; Jacquelin Feinberg; Renata Langfort; Iwona Bestry; Ewa Augustynowicz-Kopeć; Jakub Ptak; Jean-Laurent Casanova; Ewa Rowińska-Zakrzewska
Journal:  Respiration       Date:  2005-09-29       Impact factor: 3.580

9.  Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice.

Authors:  P Andersen; A B Andersen; A L Sørensen; S Nagai
Journal:  J Immunol       Date:  1995-04-01       Impact factor: 5.422

10.  Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2.

Authors:  Abebech Demissie; Markos Abebe; Abraham Aseffa; Graham Rook; Helen Fletcher; Alimuddin Zumla; Karin Weldingh; Inger Brock; Peter Andersen; T Mark Doherty
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

View more
  27 in total

Review 1.  Th17 cytokines and vaccine-induced immunity.

Authors:  Yinyao Lin; Samantha R Slight; Shabaana A Khader
Journal:  Semin Immunopathol       Date:  2010-01-30       Impact factor: 9.623

2.  Mycobacterium tuberculosis PE25/PPE41 protein complex induces activation and maturation of dendritic cells and drives Th2-biased immune responses.

Authors:  Wei Chen; Yige Bao; Xuerong Chen; Jeremy Burton; Xueli Gong; Dongqing Gu; Youjun Mi; Lang Bao
Journal:  Med Microbiol Immunol       Date:  2015-08-30       Impact factor: 3.402

3.  Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

Authors:  Hillarie Plessner Windish; Malcolm S Duthie; Ayesha Misquith; Greg Ireton; Elyse Lucas; John D Laurance; Remy H Bailor; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

4.  The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection.

Authors:  Philana Ling Lin; Jes Dietrich; Esterlina Tan; Rodolfo M Abalos; Jasmin Burgos; Carolyn Bigbee; Matthew Bigbee; Leslie Milk; Hannah P Gideon; Mark Rodgers; Catherine Cochran; Kristi M Guinn; David R Sherman; Edwin Klein; Christopher Janssen; JoAnne L Flynn; Peter Andersen
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

5.  The importance of adjuvant formulation in the development of a tuberculosis vaccine.

Authors:  Susan L Baldwin; Sylvie Bertholet; Valerie A Reese; Lance K Ching; Steven G Reed; Rhea N Coler
Journal:  J Immunol       Date:  2012-01-30       Impact factor: 5.422

6.  Expression and immunogenicity of the mycobacterial Ag85B/ESAT-6 antigens produced in transgenic plants by elastin-like peptide fusion strategy.

Authors:  Doreen Manuela Floss; Michael Mockey; Galliano Zanello; Damien Brosson; Marie Diogon; Roger Frutos; Timothée Bruel; Valérie Rodrigues; Edwin Garzon; Claire Chevaleyre; Mustapha Berri; Henri Salmon; Udo Conrad; Laurence Dedieu
Journal:  J Biomed Biotechnol       Date:  2010-04-13

Review 7.  The ABC of clinical and experimental adjuvants--a brief overview.

Authors:  Richard Brunner; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

8.  T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection.

Authors:  Karen Smith Korsholm; Rune V Petersen; Else Marie Agger; Peter Andersen
Journal:  Immunology       Date:  2009-07-14       Impact factor: 7.397

9.  The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons.

Authors:  Elizabeth C Carroll; Lei Jin; Andres Mori; Natalia Muñoz-Wolf; Ewa Oleszycka; Hannah B T Moran; Samira Mansouri; Craig P McEntee; Eimear Lambe; Else Marie Agger; Peter Andersen; Colm Cunningham; Paul Hertzog; Katherine A Fitzgerald; Andrew G Bowie; Ed C Lavelle
Journal:  Immunity       Date:  2016-03-02       Impact factor: 31.745

Review 10.  Th17 cell based vaccines in mucosal immunity.

Authors:  Pawan Kumar; Kong Chen; Jay K Kolls
Journal:  Curr Opin Immunol       Date:  2013-05-10       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.